A lignan, its preparation method and application

Abstract

This invention provides a lignan, belonging to the field of pharmaceutical technology. This invention is the first to extract, isolate, and identify compounds of formula I and formula II from Schisandra chinensis oil. Both compounds of formula I and formula II are superior to the positive control group arbutin in inhibiting melanin production in mouse skin melanoma cells (B16F10). Through experiments inhibiting the release of inflammatory factors, it was found that compounds of formula I and formula II have good activity in inhibiting the release of IL-6 and TNF-α from LPS-induced mouse monocyte-macrophage RAW264.7 cells. In skin irritation experiments, the unsaponifiables of Schisandra chinensis, including compounds of formula I and formula II, were non-irritating to rabbit skin, proving that compounds of formula I and formula II can be used to prepare whitening and anti-inflammatory products. Formula I; Formula II.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a lignan, its preparation method, and its application. Background Technology

[0002] The skin, covering the body surface, has multiple functions, including protection, absorption, secretion, aesthetics, stimulation sensing, temperature regulation, participation in the immune system, maintenance of water and electrolyte balance, and metabolism. It is one of the most important organs of the human body. As the body's external barrier, the skin is frequently stimulated by the external environment, leading to various skin problems that negatively impact people's lives. Faced with problem skin, cosmetics have brought hope. In recent years, rapid economic development and a significant improvement in living standards have led to increased attention to skin care, especially skin whitening. Skin care is closely related to skin structure, forming the theoretical basis for our research on cosmetics.

[0003] Schisandra chinensis Schisandra chinensis *Schisandra chinensis* (Turcz.) Baill. is a perennial deciduous vine belonging to the genus *Schisandra* in the family Magnoliaceae. It has a long history of use in Traditional Chinese Medicine as a tonic and strengthening agent. Modern pharmacological studies have found that the active components of *Schisandra chinensis*, such as schisandrol, schisandrin B, and schisandrol A, have significant antagonistic effects on lipid peroxidation caused by oxygen free radicals. Furthermore, lignans in *Schisandra chinensis* can reduce inflammation caused by *Propionibacterium acnes* and inhibit the release of related inflammatory factors.

[0004] Recently, with the growing trend of embracing nature, functional cosmetics based on natural plants have gained popularity among consumers. Therefore, the development of cosmetics based on the whitening and anti-inflammatory active ingredients found in Schisandra chinensis has broad prospects. Summary of the Invention

[0005] The purpose of this invention is to provide a lignan, its preparation method and application. This invention extracts, isolates and identifies compounds of formula I and formula II from Schisandra chinensis oil. These two new lignan compounds of formula I and formula II in Schisandra chinensis oil have whitening and anti-inflammatory effects and are non-irritating to the skin.

[0006] To achieve the objectives of this invention, the following technical solutions are provided:

[0007] A lignan having the structure shown in Formula I or Formula II:

[0008] Formula I; Formula II.

[0009] The present invention also provides a method for preparing the lignans described in the above technical solution. The method for preparing the lignans with the structure shown in Formula I includes the following steps:

[0010] Schisandra chinensis oil was extracted with methanol to obtain an alcohol extract;

[0011] The alcohol extract was separated by first silica gel column chromatography, and components A to L were obtained sequentially according to the elution order; the eluent used in the first silica gel column chromatography was dichloromethane and methanol;

[0012] The G component was separated by second silica gel column chromatography, and the G1 to G10 components were obtained sequentially according to the elution order; the eluents used in the second silica gel column chromatography were petroleum ether and ethyl acetate.

[0013] The G8 fraction was separated and purified by gel column chromatography, and fractions G8-1 to G8-11 were obtained sequentially according to the elution order. The chromatographic column used for the gel column separation and purification was a Sephadex LH-20 dextran gel column. The eluents were dichloromethane and methanol. The G8-3 fraction was purified by first high performance liquid chromatography to obtain lignans with the structure shown in Formula I. The mobile phase used for the first high performance liquid chromatography purification was an acetonitrile-formic acid aqueous solution.

[0014] The preparation method of the lignan with the structure shown in Formula II includes the following steps:

[0015] The G7 component was obtained according to the preparation method of the lignan with the structure shown in Formula I. The G7 component was separated by reversed-phase silica gel chromatography, and the components were obtained sequentially from G7-1 to G7-90 according to the elution order. The components from G7-55 to G7-57 were combined and purified by a second high-performance liquid chromatography to obtain the lignan with the structure shown in Formula II. The chromatographic column used for separation by reversed-phase silica gel chromatography was an ODS medium-pressure column, and the eluent used was methanol and water. The mobile phase used for purification by the second high-performance liquid chromatography was acetonitrile-formic acid aqueous solution.

[0016] Preferably, the methanol is anhydrous methanol; the volume ratio of Schisandra chinensis oil to methanol is 1:1~3; and the extraction is performed 3~5 times.

[0017] Preferably, the elution method of the first silica gel column chromatography is gradient elution, wherein the volume ratio of dichloromethane to methanol in the gradient elution is 1:0, 50:1, 25:1, 15:1, 8:1, 4:1, 2:1 and 0:1, respectively.

[0018] Preferably, the elution method of the second silica gel column chromatography is gradient elution, wherein the volume ratio of petroleum ether to ethyl acetate in the gradient elution is 1:0, 30:1, 20:1, 15:1, 10:1, 5:1, 2:1 and 0:1, respectively.

[0019] Preferably, the volume ratio of dichloromethane to methanol in the eluent used for gel column separation and purification is 1:1 to 3, and the elution method is isocratic elution.

[0020] Preferably, the elution method of the reversed-phase silica gel column is gradient elution, wherein the volume percentage of methanol in the gradient elution is 50%, 60%, 70%, 80%, 90% and 100% respectively.

[0021] Preferably, in the first high-performance liquid chromatography purification, the volume percentage of acetonitrile in the acetonitrile-formic acid aqueous solution is 40-55%; and the volume fraction of formic acid in the formic acid aqueous solution is 0.1-0.5%.

[0022] Preferably, in the second high-performance liquid chromatography purification, the volume ratio of acetonitrile in the acetonitrile-formic acid aqueous solution is 83%; and the volume fraction of formic acid in the formic acid aqueous solution is 0.1~0.5%.

[0023] The present invention also provides the application of the lignans described in the above technical solution in the preparation of whitening and anti-inflammatory products.

[0024] This invention provides a lignan having the structure shown in Formula I or Formula II. This invention is the first to extract, isolate, and identify compounds of Formula I and Formula II from Schisandra chinensis oil (Schisandra chinensis from Central China). Through whitening activity experiments, this invention found that compounds of Formula I and Formula II are superior to the positive control group arbutin in inhibiting melanin production in mouse skin melanoma cells (B16F10). Through experiments inhibiting the release of inflammatory factors, this invention found that compounds of Formula I and Formula II have good activity in inhibiting the release of IL-6 and TNF-α from LPS-induced mouse monocyte-macrophage RAW264.7 cells. Through skin irritation experiments, the unsaponifiables of Schisandra chinensis, including compounds of Formula I and Formula II, are non-irritating to rabbit skin. Therefore, compounds of Formula I and Formula II of this invention can be applied to whitening and anti-inflammatory products.

[0025] The present invention also provides a method for preparing the lignans described in the above scheme. The present invention uses anhydrous methanol to extract Schisandra chinensis oil, and the obtained alcohol extract is separated by silica gel column chromatography, reversed-phase column chromatography, gel column chromatography and high performance liquid chromatography to obtain two new lignans. The extraction and purification method provided by the present invention is simple and easy to operate. Detailed Implementation

[0026] This invention provides a lignan having the structure shown in Formula I or Formula II:

[0027] Formula I; Formula II.

[0028] The present invention also provides a method for preparing the lignans, comprising the following steps:

[0029] Schisandra chinensis oil was extracted with methanol to obtain an alcohol extract;

[0030] The alcohol extract was separated by first silica gel column chromatography, and components A to L were obtained sequentially according to the elution order; the eluent used in the first silica gel column chromatography was dichloromethane and methanol;

[0031] The G component was separated by second silica gel column chromatography, and the G1 to G10 components were obtained sequentially according to the elution order; the eluents used in the second silica gel column chromatography were petroleum ether and ethyl acetate.

[0032] The G8 fraction was separated and purified by gel column chromatography, and fractions G8-1 to G8-11 were obtained sequentially according to the elution order. The chromatographic column used for the gel column separation and purification was a Sephadex LH-20 dextran gel column. The eluents were dichloromethane and methanol. The G8-3 fraction was purified by first high performance liquid chromatography to obtain lignans with the structure shown in Formula I. The mobile phase used for the first high performance liquid chromatography purification was an acetonitrile-formic acid aqueous solution.

[0033] The preparation method of the lignan with the structure shown in Formula II includes the following steps:

[0034] The G7 component was obtained according to the preparation method of the lignan with the structure shown in Formula I. The G7 component was separated by reversed-phase silica gel chromatography, and the components were obtained sequentially from G7-1 to G7-90 according to the elution order. The components from G7-55 to G7-57 were combined and purified by a second high-performance liquid chromatography to obtain the lignan with the structure shown in Formula II. The chromatographic column used for separation by reversed-phase silica gel chromatography was an ODS medium-pressure column, and the eluent used was methanol and water. The mobile phase used for purification by the second high-performance liquid chromatography was acetonitrile-formic acid aqueous solution.

[0035] In this invention, unless otherwise specified, all raw materials are commercially available products well known to those skilled in the art.

[0036] This invention involves extracting Schisandra chinensis oil with methanol to obtain an alcohol extract. In this invention, the methanol is anhydrous methanol; the volume ratio of Schisandra chinensis oil to methanol is 1:1 to 3, and in specific embodiments, it can be 1:1 or 1:2; the extraction is performed 3 to 5 times, and the methanol phases obtained after each extraction are combined to obtain the alcohol extract; the extraction temperature is room temperature, and in specific embodiments, it can be 15 to 35°C.

[0037] In this invention, the eluent used for the first silica gel column chromatography separation is dichloromethane and methanol; the elution method is gradient elution, wherein the volume ratio of dichloromethane to methanol in the gradient elution is 1:0, 50:1, 25:1, 15:1, 8:1, 4:1, 2:1 and 0:1 respectively; the eluent used for the second silica gel column chromatography separation is petroleum ether and ethyl acetate; the elution method is gradient elution, wherein the volume ratio of petroleum ether to ethyl acetate in the gradient elution is 1:0, 30:1, 20:1, 15:1, 10:1, 5:1, 2:1 and 0:1 respectively.

[0038] In this invention, the silica gel used for the first and second silica gel column chromatography separation has a mesh size of 200-300 mesh; in this invention, the fractions obtained from the first and second silica gel column chromatography separation are identified and segmented using thin-layer chromatography (TLC), and the same components are combined and obtained sequentially according to the elution order of the components; the developing solvent used in the thin-layer chromatography is dichloromethane and methanol; the volume ratio of dichloromethane to methanol is 8-10:1.

[0039] In this invention, the eluent used for gel column separation and purification is dichloromethane and methanol. The fractions obtained in the gel column separation and purification process are identified and segmented using thin-layer chromatography. Identical components are combined, and the corresponding components are obtained sequentially according to their elution order.

[0040] In this invention, the reversed-phase silica gel column used for separation is an ODS medium-pressure column; the eluent used is methanol and water, and the elution method is gradient elution, wherein the volume percentage of methanol in the gradient elution is 50%, 60%, 70%, 80%, 90%, and 100% sequentially. The fractions obtained from the separation using the reversed-phase silica gel column of this invention are identified and segmented using thin-layer chromatography, and identical components are combined and obtained sequentially according to the elution order.

[0041] In this invention, the first high-performance liquid chromatography purification is a preparative high-performance liquid chromatography purification; the mobile phase used is an acetonitrile-formic acid aqueous solution, wherein the volume percentage of acetonitrile in the acetonitrile-formic acid aqueous solution is 40~55%, the gradient change time is 30 min, and the system uses automatic elution; the volume fraction of formic acid in the formic acid aqueous solution is 0.1~0.5%; and the flow rate of the mobile phase is 8~10 mL / min.

[0042] In this invention, the mobile phase used for the second high-performance liquid chromatography purification is an acetonitrile-formic acid aqueous solution, wherein the volume ratio of acetonitrile in the acetonitrile-formic acid aqueous solution is 83%, and the elution method is 83% isocratic elution; the volume fraction of formic acid in the formic acid aqueous solution is 0.1~0.5%; and the flow rate of the mobile phase is 8~10 mL / min.

[0043] The present invention also provides the application of the lignans described in the above technical solution in the preparation of whitening and anti-inflammatory products.

[0044] To further illustrate the present invention, the following detailed description of the lignans, their preparation methods, and applications provided by the present invention is provided in conjunction with embodiments, but these should not be construed as limiting the scope of protection of the present invention.

[0045] Example 1

[0046] Weigh 5 kg of Schisandra chinensis oil and extract it three times with 5 kg of anhydrous methanol. Combine the anhydrous methanol fractions obtained from the three extractions to obtain the alcohol extract.

[0047] 810.0 g of the alcohol extract was weighed and dissolved in anhydrous methanol. The sample was mixed with 100-200 mesh silica gel and then separated by silica gel chromatography on a first silica column. The eluents were dichloromethane and methanol, with volume ratios of 1:0, 50:1, 25:1, 15:1, 8:1, 4:1, 2:1, and 0:1, respectively. Thin-layer chromatography (TLC) was used for identification, with dichloromethane and methanol in a volume ratio of 10:1 as the developing solvent. Identical components were combined to obtain 12 fractions, which were named A to L in the order of elution.

[0048] Take 210.0 g of fraction G and redissolve it in anhydrous methanol. Mix it with 100-200 mesh silica gel. After mixing, separate it by second silica gel column chromatography. The eluent is petroleum ether and ethyl acetate. The volume ratio of petroleum ether to ethyl acetate is 1:0, 30:1, 20:1, 15:1, 10:1, 5:1, 2:1 and 0:1 respectively. TLC is used for identification. The developing solvent is dichloromethane and methanol with a volume ratio of 8:1. Combine the same components to obtain 10 fractions. According to the elution order, they are named fractions G1 to G10.

[0049] Component G8 was separated by gelation using a dichloro-methanol system. The fractions obtained from the gel column separation were identified and segmented by thin-layer chromatography. Identical components were combined to obtain 11 fractions, which were named G8-1 to G8-11 in the order of elution.

[0050] Component G8-3 was purified by preparative high performance liquid chromatography. The mobile phase was acetonitrile-0.1% formic acid water. The gradient elution program (automatic elution by the system) was 40-55% for 30 min, and the mobile phase flow rate was 8 mL / min. 8.7 mg of neolignans (compound I) from Schisandra chinensis oil was obtained, with a retention time of 22.0 min.

[0051] The structural identification of the neolignans in the obtained Schisandra chinensis oil is as follows:

[0052] Structural formula:

[0053] Compound of formula I.

[0054] Molecular formula: C 38 H 48 O8.

[0055] LC-IT-TOF m / z: 655.3242 [M+Na] + Pale yellow oily substance, specific rotation: [α]25 D-26.8 (c2.4, CH3OH);

[0056] 1 H-NMR and 13 C-NMR data are shown in Table 1.

[0057] Table 1 shows the compounds of formula I. 1 H-NMR and 13 C-NMR data

[0058]

[0059]

[0060] Example 2

[0061] Weigh 5 kg of Schisandra chinensis oil and extract it three times with 5 kg of anhydrous methanol. Combine the anhydrous methanol fractions obtained from the three extractions to obtain the alcohol extract.

[0062] 810.0 g of the alcohol extract was weighed and dissolved in anhydrous methanol. The sample was mixed with 100-200 mesh silica gel and then separated by silica gel chromatography on a first silica column. The eluents were dichloromethane and methanol, with volume ratios of 1:0, 50:1, 25:1, 15:1, 8:1, 4:1, 2:1, and 0:1, respectively. Thin-layer chromatography (TLC) was used for identification, with dichloromethane and methanol in a volume ratio of 10:1 as the developing solvent. Identical components were combined to obtain 12 fractions, which were named A to L in the order of elution.

[0063] Take 210.0 g of fraction G and redissolve it in anhydrous methanol. Mix it with 100-200 mesh silica gel. After mixing, separate it by second silica gel column chromatography. The eluent is petroleum ether and ethyl acetate. The volume ratio of petroleum ether to ethyl acetate is 1:0, 30:1, 20:1, 15:1, 10:1, 5:1, 2:1 and 0:1 respectively. TLC is used for identification. The developing solvent is dichloromethane and methanol with a volume ratio of 8:1. Combine the same components to obtain 10 fractions. According to the elution order, they are named fractions G1 to G10.

[0064] The G7 fraction was separated by passing it through an ODS medium-pressure column with methanol and water as eluents, at volume percentages of 50%, 60%, 70%, 80%, 90%, and 100%, respectively. Thin-layer chromatography (TLC) was used for identification, with dichloromethane and methanol as the developing solvent in a volume ratio of 10:1. Identical fractions were combined to obtain 90 fractions, which were then labeled as fractions G7-1 to G7-90 in elution order.

[0065] The G7-55~G7-57 fractions were purified by preparative high performance liquid chromatography. The mobile phase was acetonitrile-0.1% formic acid water: 83%, with isocratic elution and a flow rate of 8 mL / min. 3.2 mg of neolignans (compound II) in Schisandra chinensis oil was obtained, with a retention time of 35.0 min.

[0066] The structural identification of the neolignans in the obtained Schisandra chinensis oil is as follows:

[0067] Structural formula:

[0068] Compound of formula II.

[0069] Molecular formula: C 22 H 26 O5.

[0070] LC-IT-TOF m / z: 393.1674 [M+Na] + White solid; specific rotation [α]25 D 26 (c 0.9, CH3OH);

[0071] 1 H-NMR and 13 C-NMR data are shown in Table 2.

[0072] Compounds of Formula II in Table 2 1 H-NMR and 13 C-NMR data

[0073]

[0074] Test Example 1

[0075] Whitening activity test:

[0076] The cells used in this test were B16F10 mouse skin melanoma cells, and the compounds to be tested were the compound of formula I prepared in Example 1 and the compound of formula II prepared in Example 2.

[0077] Cell culture: Mouse skin melanoma B16F10 cells were cultured in 1640 medium containing 10% FBS and 100 U / mL double antibiotic solution, and placed in a 37°C, 5% CO2 cell culture incubator. When the cells reached 90% confluence, they were digested with trypsin containing 0.25% EDTA and passaged.

[0078] Cellular melanin content detection: B16F10 cells were processed at a ratio of 5 × 10⁻⁶. 4 Cells were seeded at a concentration of 2 mL / mL in 6-well cell culture plates. After 24 hours, once the cells had adhered, they were divided into three groups: a blank control group, an α-MSH model group, an α-MSH+ positive control group (arbutin), and an α-MSH+ drug administration group (compounds of formula I obtained in Example 1 and compound of formula II obtained in Example 2), with three replicates for each group. The blank control group was treated with DMEM medium containing 10% FBS, the model group was treated with medium containing 100 nmol / L α-MSH (M=1664.9), and the positive control group and drug administration group were treated with 2 mL / well of 50 μM α-MSH. The cells were then incubated in a cell culture incubator for 72 hours.

[0079] Cellular melanin inhibition rate IC 50 Measurement: The IC50 inhibition rate of melanin in the drug-treated groups with similar results to the positive control group was measured. 50 Five drug concentrations were set for each sample: 2.5, 5.0, 10.0, 20.0, and 40 μM. The experimental procedure was the same as that for the detection of cell melanin content. Data processing and analysis: Each sample was measured in triplicate, and the result was the average of the three parallel measurements. GraphPad Prism 9 statistical software was used for data analysis. Values ​​are expressed as mean ± standard deviation (x̄ ± s). One-way ANOVA was used for comparisons among multiple groups. P < 0.05 was considered statistically significant. The results are shown in Table 3.

[0080] Table 3 Melanin Inhibition Rate (IC) 50 result

[0081]

[0082] Experimental results show that the melanin content of the two lignan compounds (Formula I and Formula II) in the Schisandra chinensis oil provided by this invention is close to that of the positive control group, indicating that Formula I and Formula II compounds can inhibit melanin production in B16F10 cells.

[0083] Test Example 2

[0084] Test to inhibit the release of inflammatory factors:

[0085] In this test case, the inhibitory effects of the target compounds on TNF-α and IL-6 secretion were detected using the ELISA sandwich method in a mouse monocyte / macrophage RAW264.7 inflammation model induced by LPS lipopolysaccharide, and the anti-inflammatory effects of compounds of formula I and formula II were further evaluated.

[0086] The specific steps are as follows:

[0087] Cell culture: RAW264.7 cells in the logarithmic growth phase were scraped off using a cell scraper and suspended in high-glucose DMEM complete culture medium containing 10% fetal bovine serum to form a single-cell suspension. The suspension was cultured at 1.0 × 10⁶ cells / cells. 4 Seeds were planted at a density of 100 μL per well in 96-well plates and incubated overnight.

[0088] Adding Formula I and Formula II compounds: Induction stimulation was performed with 1 μg / mL LPS, and Formula I and Formula II compounds were added simultaneously for treatment. A drug-free group (and model group), a normal group (without LPS) and a positive drug group (dexamethasone, 10 μM) were set up. Each treatment was set up with 3 replicates and cultured at 37°C and 5% CO2 for 24 hours.

[0089] Cytokine detection: Centrifuge 300g of cell culture supernatant for 10min, and detect the levels of TNF-α and IL-6 according to the kit instructions.

[0090] Cell viability assay: Discard the culture medium in each well, add a 4:1 mixture of culture medium and MTS (100 μL per well), and set up 3 blank replicates. Incubate for 2-4 hours, measure the absorbance at 490 nm using a multi-mode microplate reader, and record the results. Calculate the cell viability using Equation 1.

[0091] Survival rate % = (OD value of experimental group - OD value of blank group) / (OD value of negative group - OD value of blank group) × 100% Equation 1;

[0092] The results of the compound of formula II inhibiting the production of inflammatory mediators IL-6 and TNF-α induced by LPS in RAW264.7 cells are shown in Table 4.

[0093] Table 4 shows that compound II inhibits LPS-induced inflammatory mediators IL-6 and TNF-α in RAW264.7 cells. α The result of

[0094]

[0095] Note: Compared with the blank group in Table 4. ### P<0.001; compared with the model group P<0.001.

[0096] Experimental results show that, compared with the LPS model group, the new lignan compound of formula II in Schisandra chinensis oil provided by this invention can effectively inhibit the release of LPS-induced IL-6 and TNF-α.

[0097] Test Example 3

[0098] Skin irritation test:

[0099] The experimental animals used in this test case were Japanese white rabbits, and the test compounds were the unsaponifiable methanol extract of Schisandra chinensis oil, the compound of formula I prepared in Example 1, and the compound of formula II prepared in Example 2.

[0100] The specific steps are as follows:

[0101] Three Japanese white rabbits were used. Twenty-four hours before drug administration, all rabbits underwent hair removal (both sides of the spine) and disinfection. The hair removal area was 5cm x 5cm. For the damaged skin group, a crisscross pattern was made on the bald area using a sterile syringe needle, 1mm deep, until slight bleeding occurred in the epidermis. Each incision was approximately 2cm long and considered as damaged skin. The experiment used a self-comparison method between the left and right sides of the same animal. Two 5cm x 5cm areas were taken from each rabbit on both sides of the spine, resulting in four skin test areas per rabbit. The three Japanese white rabbits had a total of 12 skin test areas: 6 for intact skin and 6 for damaged skin. The intact skin areas were encapsulated with transparent film, covered with non-irritating gauze, and secured with tape. Twenty-four hours after drug administration, the test drug was removed with physiological saline. At 1 hour, 24 hours, 48 ​​hours, and 72 hours after drug removal, the presence and resolution of local skin reactions such as erythema and edema were observed and recorded.

[0102] Experimental results show that after 72 hours of application of compounds I and II, the lightness L value (fair and smooth) of the damaged skin was higher than that of the control group, and there was no erythema or edema compared with the control group, indicating that it was not irritating to the skin of rabbits. This indicates that the two new lignan compounds I and II in the Schisandra chinensis oil provided by this invention are not irritating to the skin of rabbits.

[0103] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A lignan, characterized in that, A lignan having a structure shown in Formula II: Formula II.

2. The method of claim 1, wherein the lignan is prepared by the steps of, The preparation method of the lignan having a structure shown in Formula II comprises the following steps: The Schisandra oil is extracted by methanol to obtain an alcohol extract; The alcohol extract is separated by a first silica gel column chromatography to obtain components A-L in sequence according to the component elution order; the eluent used in the first silica gel column chromatography is dichloromethane and methanol; The G component is separated by a second silica gel column chromatography to obtain components G1-G10 in sequence according to the component elution order; the eluent used in the second silica gel column chromatography is petroleum ether and ethyl acetate; The G7 component is separated by a reversed-phase silica gel column chromatography to obtain components G7-1-G7-90 in sequence according to the component elution order, and components G7-55-G7-57 are combined and purified by a second high-performance liquid chromatography to obtain the lignan having a structure shown in Formula II; the reversed-phase silica gel column chromatography uses an ODS medium-pressure column, and the eluent is methanol and water; the second high-performance liquid chromatography uses a mobile phase of acetonitrile and a methanoic acid aqueous solution.

3. The preparation method according to claim 2, characterized in that, The methanol is anhydrous methanol; the volume ratio of the Schisandra oil and the methanol is 1:1-3; and the extraction is performed for 3-5 times.

4. The production method according to claim 2, characterized by, The elution mode of the first silica gel column chromatography is gradient elution, and the volume ratio of dichloromethane and methanol in the gradient elution is 1:0, 50:1, 25:1, 15:1, 8:1, 4:1, 2:1 and 0:1 in sequence.

5. The preparation method according to claim 2, characterized in that, The elution mode of the second silica gel column chromatography is gradient elution, and the volume ratio of petroleum ether and ethyl acetate in the gradient elution is 1:0, 30:1, 20:1, 15:1, 10:1, 5:1, 2:1 and 0:1 in sequence.

6. The method of claim 2, wherein, The elution mode of the reversed-phase silica gel column chromatography is gradient elution, and the volume percentage of methanol in the gradient elution is 50%, 60%, 70%, 80%, 90% and 100% in sequence.

7. The preparation method according to claim 2, characterized in that, In the second high-performance liquid chromatography purification, the volume ratio of acetonitrile in the acetonitrile-methanoic acid aqueous solution is 83%, and the volume fraction of methanoic acid in the methanoic acid aqueous solution is 0.1-0.5%.

Images